Published in:

01-04-2021 | Hemolytic Uremic Syndrome | Correction

Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Authors: Kazuki Tanaka, Brigitte Adams, Alvaro Madrid Aris, Naoya Fujita, Masayo Ogawa, Stephan Ortiz, Marc Vallee, Larry A. Greenbaum

Published in: Pediatric Nephrology | Issue 4/2021